Please provide your email address to receive an email when new articles are posted on . A novel blood test that measures elevated circulating cell-free DNA may be used to evaluate disease severity and ...

Results for the STELLAR trial, presented at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology, hit nearly every mark: patients taking ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...

Patients can “Outnumber PAH” by developing a strong support team, advises an unbranded educational campaign launched by Merck against pulmonary arterial hypertension (PAH), a rare, progressive disease ...

NEW ORLEANS, LA—Sotatercept, a first-in-class, investigational activin receptor type IIA-Fc fusion protein, taken on top of approved medications, improves 6-minute walk test over 24 weeks in patients ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

Please provide your email address to receive an email when new articles are posted on . CS1 is an oral histone deacetylase inhibitor that has been shown to be well tolerated in patients with PAH in a ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) prevalence is higher among Medicaid beneficiaries, with significant racial and ethnic disparities, particularly affecting Black ...